You are here

  • Home
  • Archive
  • Volume 80, Issue 8
  • Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

Article metrics

Article menu
XML
Spondyloarthritis
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

 

Online download statistics by month:

Online download statistics by month: April 2021 to March 2024

AbstractFullPdf
Apr 202116451621729
May 2021701697176
Jun 2021213213113
Jul 2021705703236
Aug 2021409403155
Sep 202129729593
Oct 202117417082
Nov 202127527471
Dec 202127527358
Jan 202223923955
Feb 202214614382
Mar 202216916652
Apr 202217516966
May 202218117866
Jun 202215114887
Jul 202212012546
Aug 202214814973
Sep 202217718563
Oct 202215713049
Nov 202214011346
Dec 2022716743
Jan 2023978240
Feb 20231039343
Mar 202310710446
Apr 2023858446
May 2023898738
Jun 2023858253
Jul 2023514834
Aug 2023595919
Sep 2023545119
Oct 2023737228
Nov 20231089034
Dec 20231058751
Jan 2024846143
Feb 2024685434
Mar 2024796776
Total781575823045